Movement Alert｜Eli Lilly Rises 3.29% in Regular Trading, Leukemia Drug Jaypirca Receives Positive EU CHMP Opinion

Market Focus06-26 22:24

On June 26, Eli Lilly rose 3.29% in regular trading, reaching $1,195.165 per share with turnover of $1.51 billion, hitting an all-time high.

On the news front, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. The recommendation was based on two Phase 3 trials — BRUIN CLL-313 and BRUIN CLL-314 — both of which met their primary endpoints. A final decision by the European Commission is expected within one to two months. Eli Lilly has also submitted these trial results to the U.S. FDA, with a decision anticipated in the second half of this year.

Additionally, Eli Lilly's Onswik received a separate positive EU regulatory recommendation. Leerink Partners raised its price target on the stock to $1,232 from $1,119, maintaining an Outperform rating. The consensus mean target stands at $1,261.48, reinforcing bullish sentiment around the company's expanding pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158307938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 22:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158307938","market":"us","top_or_hot":-1,"title":"Movement Alert｜Eli Lilly Rises 3.29% in Regular Trading, Leukemia Drug Jaypirca Receives Positive EU CHMP Opinion","media":"Market Focus","content":"<p><p>On June 26, Eli Lilly rose 3.29% in regular trading, reaching $1,195.165 per share with turnover of $1.51 billion, hitting an all-time high.</p><p>On the news front, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. The recommendation was based on two Phase 3 trials — BRUIN CLL-313 and BRUIN CLL-314 — both of which met their primary endpoints. A final decision by the European Commission is expected within one to two months. Eli Lilly has also submitted these trial results to the U.S. FDA, with a decision anticipated in the second half of this year.</p><p>Additionally, Eli Lilly's Onswik received a separate positive EU regulatory recommendation. Leerink Partners raised its price target on the stock to $1,232 from $1,119, maintaining an Outperform rating. The consensus mean target stands at $1,261.48, reinforcing bullish sentiment around the company's expanding pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Eli Lilly Rises 3.29% in Regular Trading, Leukemia Drug Jaypirca Receives Positive EU CHMP Opinion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Eli Lilly Rises 3.29% in Regular Trading, Leukemia Drug Jaypirca Receives Positive EU CHMP Opinion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 22:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Eli Lilly rose 3.29% in regular trading, reaching $1,195.165 per share with turnover of $1.51 billion, hitting an all-time high.</p><p>On the news front, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. The recommendation was based on two Phase 3 trials — BRUIN CLL-313 and BRUIN CLL-314 — both of which met their primary endpoints. A final decision by the European Commission is expected within one to two months. Eli Lilly has also submitted these trial results to the U.S. FDA, with a decision anticipated in the second half of this year.</p><p>Additionally, Eli Lilly's Onswik received a separate positive EU regulatory recommendation. Leerink Partners raised its price target on the stock to $1,232 from $1,119, maintaining an Outperform rating. The consensus mean target stands at $1,261.48, reinforcing bullish sentiment around the company's expanding pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1158307938","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158307938","pubTimestamp":1782483858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Eli Lilly rose 3.29% in regular trading, reaching $1,195.165 per share with turnover of $1.51 billion, hitting an all-time high.On the news front, the European Medicines Agency's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"动向预警|礼来常规交易涨3.29%白血病药物Jaypirca获欧盟CHMP正面意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"On June 26, Eli Lilly rose 3.29% in regular trading, reaching $1,195.165 per share with turnover of $1.51 billion, hitting an all-time high.On the news front, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. The recommendation was based on two Phase 3 trials — BRUIN CLL-313 and BRUIN CLL-314 — both of which met their primary endpoints. A final decision by the European Commission is expected within one to two months. Eli Lilly has also submitted these trial results to the U.S. FDA, with a decision anticipated in the second half of this year.Additionally, Eli Lilly's Onswik received a separate positive EU regulatory recommendation. Leerink Partners raised its price target on the stock to $1,232 from $1,119, maintaining an Outperform rating. The consensus mean target stands at $1,261.48, reinforcing bullish sentiment around the company's expanding pipeline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158307938","isCrawlerRequest":true}